Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

Related Keywords

Germany ,United States ,United Kingdom ,American ,Gerard Michel ,American Society Of Clinical Oncology ,Prnewswire Delcath Systems Inc ,Drug Administration ,Nasdaq ,Exchange Commission ,Access Program ,Delcath Systems Inc ,American Society ,Clinical Oncology ,Expanded Access Program ,Predictive Parameters ,Unresectable Liver Metastases ,Uveal Melanoma ,Retrospective Pooled Analysis ,Interventional Radiology ,Hepatic Delivery System ,Hepzato Kit ,Chief Executive Officer ,Sheet Highlights ,Common Stock ,Pre Funded Warrants ,Private Placement ,Monday August ,Toll Free ,Delcath Systems ,United States Food ,Delivery System ,Private Securities Litigation Reform Act ,Individual Funding Requests ,Stockholder Equity ,Consolidated Statements ,Nc ,